From modules to medicine: How modular domains and their associated networks can enable personalized medicine

FEBS Letters

Volumn 586, Issue 17, 2012, Pages 2580-2585

  Haura, Eric B ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Cancer; Domain; Kinase inhibitor; Personalized medicine; SH2; Tyrosine kinase

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHOTYROSINE; PROTEIN SH2; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR;

CANCER GENETICS; GENE EXPRESSION PROFILING; GENOTYPE; HUMAN; MOLECULARLY TARGETED THERAPY; MUTATIONAL ANALYSIS; ONCOGENE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; GENOMICS; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; MASS SPECTROMETRY; NEOPLASMS; PHOSPHORYLATION; PHOSPHOTYROSINE; PROTEIN INTERACTION MAPPING; PROTEIN STRUCTURE, TERTIARY; PROTEIN-TYROSINE KINASES; PROTEINS; SRC HOMOLOGY DOMAINS;

EID: 84864587950     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2012.04.036     Document Type: Review

References (65)

1. G.W. Sledge Jr. The challenge and promise of the genomic era J. Clin. Oncol. 30 2012 203 209 10.1200/JCO.2011.39.0088
2. B.J. Druker, and A. David Karnofsky Award lecture. Imatinib as a paradigm of targeted therapies J. Clin. Oncol. 21 2003 239s 245s
3. J. Baselga Targeting tyrosine kinases in cancer: the second wave Science 312 2006 1175 1178
4. W. Pao, and N. Girard New driver mutations in non-small-cell lung cancer Lancet Oncol. 12 2011 175 180 doi: 10.1016/S1470-2045(10)70087-5
5. W. Pao, and K.E. Hutchinson Chipping away at the lung cancer genome Nat. Med. 18 2012 349 351 doi: 10.1038/nm.2697
6. K. Bergethon, A.T. Shaw, S.H. Ou, R. Katayama, C.M. Lovly, N.T. McDonald, P.P. Massion, C. Siwak-Tapp, A. Gonzalez, and R. Fang ROS1 rearrangements define a unique molecular class of lung cancers J. Clin. Oncol. 30 2012 863 870 doi: 10.1200/JCO.2011.35.6345
7. Pao, W., Chmielecki, J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10, 760-774, doi: nrc2947[pii]10.1038/nrc2947.
8. G.J. Riely, W. Pao, D. Pham, A.R. Li, N. Rizvi, E.S. Venkatraman, M.F. Zakowski, M.G. Kris, M. Ladanyi, and V.A. Miller Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib Clin. Cancer Res. 12 2006 839 844 doi: 12/3/839[pii]10.1158/1078-0432.CCR-05-1846
9. W. Pao, and J. Chmielecki Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer Nat. Rev. Cancer 10 2010 760 774 doi: 10.1038/nrc2947
10. R.A. Gatenby, and R.J. Gillies A microenvironmental model of carcinogenesis Nat. Rev. Cancer 8 2008 56 61 doi: 10.1038/nrc2255
11. T.A. Yap, M. Gerlinger, P.A. Futreal, L. Pusztai, and C. Swanton Intratumor heterogeneity: seeing the wood for the trees Sci. Transl. Med. 4 2012 127ps110 doi: 10.1126/scitranslmed.3003854
12. K.Y. Su, H.Y. Chen, K.C. Li, M.L. Kuo, J.C. Yang, W.K. Chan, B.C. Ho, G.C. Chang, J.Y. Shih, and S.L. Yu Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer J. Clin. Oncol. 30 2012 433 440 doi: 10.1200/JCO.2011.38.3224
13. Fojo T & Parkinson DR Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? Clin Cancer Res 16, 5972-5980, doi: 16/24/5972 [pii] 10.1158/1078-0432.CCR-10-1277.
14. A.L. Barabasi, and Z.N. Oltvai Network biology: understanding the cell's functional organization Nat. Rev. Genet. 5 2004 101 113 doi: 10.1038/nrg1272 nrg1272 [pii]
15. K.I. Goh, M.E. Cusick, D. Valle, B. Childs, M. Vidal, and A.L. Barabasi The human disease network Proc. Natl. Acad. Sci. USA 104 2007 8685 8690 doi: 0701361104 [pii] 10.1073/pnas.0701361104
16. M.A. Yildirim, K.I. Goh, M.E. Cusick, A.L. Barabasi, and M. Vidal Drug-target network Nat. Biotechnol. 25 2007 1119 1126 doi: nbt1338 [pii] 10.1038/nbt1338
17. R. Sordella, D.W. Bell, D.A. Haber, and J. Settleman Gefitinib- sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways Science 305 2004 1163 1167
18. A.C. Faber, D. Li, Y. Song, M.C. Liang, B.Y. Yeap, R.T. Bronson, E. Lifshits, Z. Chen, S.M. Maira, and C. Garcia-Echeverria Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition Proc. Natl. Acad. Sci. USA 106 2009 19503 19508 doi: 0905056106 [pii] 10.1073/pnas.0905056106
19. T. Glatter, A. Wepf, R. Aebersold, and M. Gstaiger An integrated workflow for charting the human interaction proteome: insights into the PP2A system Mol. Syst. Biol. 5 2009 237 doi: msb200875 [pii] 10.1038/msb.2008.75
20. M. Gstaiger, and R. Aebersold Applying mass spectrometry-based proteomics to genetics, genomics and network biology Nat. Rev. Genet. 10 2009 617 627 doi: nrg2633 [pii] 10.1038/nrg2633
21. A.L. Barabasi Network medicine - from obesity to the " diseasome" N. Engl. J. Med. 357 2007 404 407 doi: NEJMe078114 [pii] 10.1056/NEJMe078114
22. J. Lim, T. Hao, C. Shaw, A.J. Patel, G. Szabo, J.F. Rual, C.J. Fisk, N. Li, A. Smolyar, and D.E. Hill A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration Cell 125 2006 801 814 doi: S0092-8674(06)00439-9 [pii] 10.1016/j.cell.2006.03.032
23. I.W. Taylor, R. Linding, D. Warde-Farley, Y. Liu, C. Pesquita, D. Faria, S. Bull, T. Pawson, Q. Morris, and J.L. Wrana Dynamic modularity in protein interaction networks predicts breast cancer outcome Nat. Biotechnol. 27 2009 199 204 doi: nbt.1522 [pii] 10.1038/nbt.1522
24. Q. Cui, Y. Ma, M. Jaramillo, H. Bari, A. Awan, S. Yang, S. Zhang, L. Liu, M. Lu, and M. O'Connor-McCourt A map of human cancer signaling Mol. Systems Biol. 3 2007 152 doi: 10.1038/msb4100200
25. T. Pawson, and R. Linding Network medicine FEBS Lett. 582 2008 1266 1270 doi: S0014-5793(08)00115-4 [pii] 10.1016/j.febslet.2008.02.011
26. A. Bhattacharjee, W.G. Richards, J. Staunton, C. Li, S. Monti, P. Vasa, C. Ladd, J. Beheshti, R. Bueno, and M. Gillette Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses Proc. Natl. Acad. Sci. USA 98 2001 13790 13795
27. T.R. Golub, D.K. Slonim, P. Tamayo, C. Huard, M. Gaasenbeek, J.P. Mesirov, H. Coller, M.L. Loh, J.R. Downing, and M.A. Caligiuri Molecular classification of cancer: class discovery and class prediction by gene expression monitoring Science 286 1999 531 537
28. K. Rikova, A. Guo, Q. Zeng, A. Possemato, J. Yu, H. Haack, J. Nardone, K. Lee, C. Reeves, and Y. Li Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer Cell 131 2007 1190 1203
29. C.S. Tan, B. Bodenmiller, A. Pasculescu, M. Jovanovic, M.O. Hengartner, C. Jorgensen, G.D. Bader, R. Aebersold, T. Pawson, and R. Linding Comparative analysis reveals conserved protein phosphorylation networks implicated in multiple diseases Sci. Signal. 2 2009 ra39 doi: 10.1126/scisignal.2000316
30. L. Li, C. Tibiche, C. Fu, T. Kaneko, M.F. Moran, M.R. Schiller, S.S. Li, and E. Wang The human phosphotyrosine signaling network: Evolution and hotspots of hijacking in cancer Genome Res. 2012 doi: 10.1101/gr.128819.111
31. T. Pawson Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems Cell 116 2004 191 203
32. K. Machida, and B.J. Mayer The SH2 domain: versatile signaling module and pharmaceutical target Biochim Biophys Acta Proteins and Proteomics 1747 2005 1 25
33. B.A. Liu, E. Shah, K. Jablonowski, A. Stergachis, B. Engelmann, and P.D. Nash The SH2 domain-containing proteins in 21 species establish the provenance and scope of phosphotyrosine signaling in eukaryotes Sci. Signal. 4 2011 ra83 doi: 10.1126/scisignal.2002105
34. B.A. Liu, K. Jablonowski, M. Raina, M. Arce, T. Pawson, and P.D. Nash The human and mouse complement of SH2 domain proteins-establishing the boundaries of phosphotyrosine signaling Mol. Cell 22 2006 851 868 10.1016/j.molcel.2006.06. 001
35. K. Machida, C.M. Thompson, K. Dierck, K. Jablonowski, S. Kärkkäinen, B. Liu, H. Zhang, P.D. Nash, D.K. Newman, and P. Nollau High-throughput phosphotyrosine profiling using SH2 domains Mol. Cell 26 2007 899 915
36. K. Dierck, K.A.V. Machida, J. Thimm, M. Horstmann, W. Fiedler, B.J. Mayer, and P. Nollau Quantitative multiplexed profiling of cellular signaling networks using phosphotyrosine-specific DNA-tagged SH2 domains Nat. Meth. 3 2006 737 744
37. K. Machida, B.J. Mayer, and P. Nollau Profiling the global tyrosine phosphorylation state Mol. Cell. Proteomics 2 2003 215 233
38. P. Nollau, and B.J. Mayer Profiling the global tyrosine phosphorylation state by Src Homology 2 domain binding Proc. Natl. Acad. Sci. USA 98 2001 13531 13536
39. K. Machida, S. Eschrich, J. Li, Y. Bai, J. Koomen, B.J. Mayer, and E.B. Haura Characterizing tyrosine phosphorylation signaling in lung cancer using SH2 profiling PLoS ONE 5 2010 e13470 10.1371/journal.pone.0013470
40. L.V. Sequist, B.A. Waltman, D. Dias-Santagata, S. Digumarthy, A.B. Turke, P. Fidias, K. Bergethon, A.T. Shaw, S. Gettinger, and A.K. Cosper Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors Sci. Transl. Med. 3 2011 75ra26 10.1126/scitranslmed.3002003
41. H.W. Cheung, J. Du, J. Boehm, F. He, B. Weir, X. Wang, M. Butaney, L. Sequist, B. Luo, J. Engelman, D. Root, M. Meyerson, T. Golub, P. Janne, and W. Hahn Amplification of CRKL Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Non-Small Cell Lung Cancers Cancer Disc. 2011
42. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, B.W. Brannigan, P.L. Harris, S.M. Haserlat, J.G. Supko, and F.G. Haluska Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 350 2004 2129 2139
43. J.G. Paez, P.A. Janne, J.C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F.J. Kaye, N. Lindeman, and T.J. Boggon EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500 doi: 10.1126/science.1099314 1099314 [pii]
44. W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, B. Singh, R. Heelan, V. Rusch, and L. Fulton EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc. Natl. Acad. Sci. USA 101 2004 13306 13311
45. Haura EB, Muller A, Brietwieser FP, Li J, Grebien F, Colinge J & Bennett KL Using iTRAQ(R) Combined with Tandem Affinity Purification to Enhance Low-abundance Proteins Associated with Somatically-mutated EGFR Core Complexes in Lung Cancer. J Proteome Res, doi: 10.1021/pr100863f.
46. S. Massinen, K. Tammimies, I. Tapia-Paez, H. Matsson, M.E. Hokkanen, O. Soderberg, U. Landegren, E. Castren, J.A. Gustafsson, and E. Treuter Functional interaction of DYX1C1 with estrogen receptors suggests involvement of hormonal pathways in dyslexia Hum. Mol. Genet. 18 2009 2802 2812 doi: ddp215 [pii] 10.1093/hmg/ddp215
47. O. Soderberg, K.J. Leuchowius, M. Gullberg, M. Jarvius, I. Weibrecht, L.G. Larsson, and U. Landegren Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay Methods 45 2008 227 232 doi: S1046-2023(08)00107-2 [pii] 10.1016/j.ymeth.2008.06.014
48. J. Melin, J. Jarvius, C. Larsson, O. Soderberg, U. Landegren, and M. Nilsson Ligation-based molecular tools for lab-on-a-chip devices Nat. Biotechnol. 25 2008 42 48 doi: S1871-6784(08)00005-8 [pii] 10.1016/j.nbt.2008. 02.003
49. O. Soderberg, K.J. Leuchowius, M. Kamali-Moghaddam, M. Jarvius, S. Gustafsdottir, E. Schallmeiner, M. Gullberg, J. Jarvius, and U. Landegren Proximity ligation: a specific and versatile tool for the proteomic era Genet. Eng. (NY) 28 2007 85 93
50. M. Jarvius, J. Paulsson, I. Weibrecht, K.J. Leuchowius, A.C. Andersson, C. Wahlby, M. Gullberg, J. Botling, T. Sjoblom, and B. Markova In situ detection of phosphorylated platelet-derived growth factor receptor beta using a generalized proximity ligation method Mol. Cell. Proteomics 6 2007 1500 1509 doi: M700166-MCP200 [pii] 10.1074/mcp.M700166-MCP200
51. O. Soderberg, M. Gullberg, M. Jarvius, K. Ridderstrale, K.J. Leuchowius, J. Jarvius, K. Wester, P. Hydbring, F. Bahram, and L.G. Larsson Direct observation of individual endogenous protein complexes in situ by proximity ligation Nat. Methods 3 2006 995 1000 doi: nmeth947 [pii] 10.1038/nmeth947
52. B.A. Weir, M.S. Woo, G. Getz, S. Perner, L. Ding, R. Beroukhim, W.M. Lin, M.A. Province, A. Kraja, and L.A. Johnson Characterizing the cancer genome in lung adenocarcinoma Nature 450 2007 893 898 doi: nature06358 [pii] 10.1038/nature06358
53. M. Meyerson Cancer: broken genes in solid tumours Nature 448 2007 545 546 doi: 448545a[pii]10.1038/448545a
54. W.C. Hahn, S.A. Stewart, M.W. Brooks, S.G. York, E. Eaton, A. Kurachi, R.L. Beijersbergen, J.H. Knoll, M. Meyerson, and R.A. Weinberg Inhibition of telomerase limits the growth of human cancer cells Nat. Med. 5 1999 1164 1170 doi: 10.1038/13495
55. J. Li, A.E. Lenferink, Y. Deng, C. Collins, Q. Cui, E.O. Purisima, M.D. O'Connor-McCourt, and E. Wang Identification of high-quality cancer prognostic markers and metastasis network modules Nat. Commun. 1 2010 34 doi: 10.1038/ncomms1033
56. Broder S Twenty-five years of translational medicine in antiretroviral therapy: promises to keep. Sci Transl Med 2, 39ps33, doi: 2/39/39ps33 [pii] 10.1126/scitranslmed.3000749.
57. LoRusso, P.M., Anderson, A.B., Boerner, S.A., Averbuch SD Making the investigational oncology pipeline more efficient and effective: are we headed in the right direction? Clin Cancer Res 16, 5956-5962, doi: 16/24/5956 [pii] 10.1158/1078-0432.CCR-10-1279.
58. LoRusso, P.M., Schnipper, L.E., Stewart, D.J., Boerner, S.A., Averbuch, S.D., Wolf, W. Translating clinical trials into meaningful outcomes. Clin Cancer Res 16, 5951-5955, doi: 16/24/5951 [pii] 10.1158/1078-0432.CCR-10-2632.
59. J.M. Koomen, E.B. Haura, G. Bepler, R. Sutphen, E.R. Remily-Wood, K. Benson, M. Hussein, L.A. Hazlehurst, T.J. Yeatman, and L.T. Hildreth Proteomic contributions to personalized cancer care Mol. Cell. Proteomics 7 2008 1780 1794 doi: R800002-MCP200 [pii] 10.1074/mcp.R800002-MCP200
60. A. Whitty, and G. Kumaravel Between a rock and a hard place? Nat. Chem. Biol. 2 2006 112 118 doi: 10.1038/nchembio0306-112
61. O. Fedorov, S. Muller, and S. Knapp The (un)targeted cancer kinome Nat. Chem. Biol. 6 2010 166 169 doi: 10.1038/nchembio.297
62. M.R. Arkin, and A. Whitty The road less traveled: modulating signal transduction enzymes by inhibiting their protein-protein interactions Curr. Opin. Chem. Biol. 13 2009 284 290 10.1016/j.cbpa.2009.05.125
63. L.D. Walensky From Mitochondrial Biology to Magic Bullet: Navitoclax Disarms BCL-2 in Chronic Lymphocytic Leukemia J. Clin. Oncol. 30 2012 554 557 doi: 10.1200/JCO.2011.37.9339
64. J.J. Hwang, J. Kuruvilla, D. Mendelson, M.J. Pishvaian, J.F. Deeken, L.L. Siu, M.S. Berger, J. Viallet, and J.L. Marshall Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma Clin. Cancer Res. 16 2010 4038 4045 doi: 10.1158/1078-0432.CCR-10-0822
65. A.W. Roberts, J.F. Seymour, J.R. Brown, W.G. Wierda, T.J. Kipps, S.L. Khaw, D.A. Carney, S.Z. He, D.C. Huang, and H. Xiong Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease J. Clin. Oncol. 30 2012 488 496 doi: 10.1200/JCO.2011.34.7898